The primary objectives of the collaboration include the identification of novel biomarkers and the enhancement of clinical trial design and execution in the field of healthcare
Verily partners with Kyverna Therapeutics to advance cell therapy for autoimmune diseases. (Credit: Colin Behrens from Pixabay)
Verily, a precision health technology company of Alphabet, has announced a multi-year collaboration with Kyverna Therapeutics, a clinical-stage cell therapy company.
The primary objectives of the collaboration include the identification of novel biomarkers and the enhancement of clinical trial design and execution in the field of healthcare.
The initial phase of this partnership centres on the utilisation of Verily’s immune mapping platform known as Immune Profiler. This platform will be employed to unravel biomarkers that indicate treatment response in autoimmune patients undergoing treatment with Kyverna’s KYV-101.
KYV-101 is an autologous Chimeric Antigen Receptor (CAR) T-cell therapy currently undergoing Phase 1 clinical trials in both the US and Europe.
Verily molecular science head Charlie Kim said: “B cell depletion using CAR T-cells represents a new frontier with curative potential for autoimmune patients, and together we will be uncovering the biological basis of the immune reset that confers durable therapeutic response in these patients.”
Immune Profiler, characterised by its high-resolution molecular phenotyping and advanced computational analytics, is poised to facilitate the thorough examination of various immune functions throughout the course of CAR T-cell therapy. This approach offers an unprecedented perspective on biological activity and responses over time.
Kyverna, on the other hand, contributes a valuable network of research-ready participants and an expanding sample library derived from treating autoimmune patients across multiple indications and geographic regions using KYV-101.
KYV-101 is Kyverna’s fully human anti-CD19 CAR T-cell therapy, marking it as a significant asset for this collaborative effort in understanding and advancing immunotherapies.
Kyverna chief medical officer James Chung said: “We are excited to explore our emerging patient data set, which will enable us to generate a first look into the biology underlying immune reset after administration of CAR T-cell therapy.”
In a strategic collaboration, Verily and Kyverna will integrate digital tools and technology solutions to reshape the process of evidence generation. Their approach will prioritise a participant-centred study design that derives insights not only from data collected at study sites but also from real-world settings. This innovative methodology aims to enhance the understanding of treatment outcomes and experiences.
Furthermore, the collaboration will lead to the development of solutions tailored to meet the unique needs of autoimmune patients undergoing CAR T-cell therapy. This patient-centric approach seeks to optimize the effectiveness and patient experience within this specific therapeutic context.
Kyverna CEO Peter Maag said: “We are pleased to partner with Verily based on our shared vision to create the future landscape of clinical research, and to enable broader data collection from real-world settings that may contribute to regulatory decision-making.”
Verily product development president and chief medical officer Amy Abernethy said: “This collaboration links Verily’s deep molecular capabilities with its extensive suite of tools for real-world evidence generation, providing a comprehensive and detailed understanding of the biology and participant experience with this new therapeutic modality in autoimmune disease.”